Stay updated with breaking news from 37555810. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Gilead Sciences (NASDAQ:GILD – Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share guidance of 3.450-3.850 for the period, compared to the consensus earnings per share estimate of 3.670. The company issued revenue guidance of $27.1 billion-$27.5 billion, compared to the consensus revenue […]
StockNews.com upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a buy rating to a strong-buy rating in a research note published on Saturday. A number of other equities analysts have also recently issued reports on GILD. Royal Bank of Canada cut their target price on shares of Gilead Sciences from $76.00 to $74.00 […]
StockNews.com upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a buy rating to a strong-buy rating in a research report released on Saturday morning. A number of other research firms have also recently commented on GILD. Cantor Fitzgerald cut their target price on shares of Gilead Sciences from $80.00 to $78.00 and set […]
Gilead Sciences (NASDAQ:GILD – Get Free Report) updated its FY 2024 earnings guidance on Thursday. The company provided EPS guidance of 3.450-3.850 for the period, compared to the consensus EPS estimate of 3.670. The company issued revenue guidance of $27.1 billion-$27.5 billion, compared to the consensus revenue estimate of $25.7 billion. Gilead Sciences also updated […]
Gilead Sciences (NASDAQ:GILD – Free Report) had its price target decreased by TD Cowen from $90.00 to $85.00 in a report released on Friday, Benzinga reports. TD Cowen currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also commented on GILD. Wells Fargo & Company decreased their price target […]